Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.37
(
1.68%
)
Bitcoin
71,156.63
(
-0.12%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 159024

Saturday, 06/22/2013 6:38:05 PM

Saturday, June 22, 2013 6:38:05 PM

Post# of 257257
ABBV/ENTA will start a phase-1 trial of ABT-493 (ENTA’s next-gen PI, which is licensed to ABBV) + ABT-530 (ABBV’s own next-generation NS5A) in 3Q13. Unlike ABT-450, ABT-493 does not require ritonavir boosting and it is small enough to be combined with ABT-530 in a single qD tablet.

The combination may have utility beyond genotype-1, although the companies have not yet made specific claims. (Source: ENTA’s recent WF webcast.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now